CL2018001297A1 - Proceso para preparar una formulación en polvo seco que comprende un anticolinérgico, un corticosteroide y un beta-adrenérgico - Google Patents

Proceso para preparar una formulación en polvo seco que comprende un anticolinérgico, un corticosteroide y un beta-adrenérgico

Info

Publication number
CL2018001297A1
CL2018001297A1 CL2018001297A CL2018001297A CL2018001297A1 CL 2018001297 A1 CL2018001297 A1 CL 2018001297A1 CL 2018001297 A CL2018001297 A CL 2018001297A CL 2018001297 A CL2018001297 A CL 2018001297A CL 2018001297 A1 CL2018001297 A1 CL 2018001297A1
Authority
CL
Chile
Prior art keywords
polvo
inhalador
seco
para
prolongada
Prior art date
Application number
CL2018001297A
Other languages
English (en)
Inventor
Claudio Cafiero
Leonardo Ortenzi
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54548063&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2018001297(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of CL2018001297A1 publication Critical patent/CL2018001297A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/194Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
CL2018001297A 2015-11-16 2018-05-14 Proceso para preparar una formulación en polvo seco que comprende un anticolinérgico, un corticosteroide y un beta-adrenérgico CL2018001297A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15194661 2015-11-16

Publications (1)

Publication Number Publication Date
CL2018001297A1 true CL2018001297A1 (es) 2018-08-10

Family

ID=54548063

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018001297A CL2018001297A1 (es) 2015-11-16 2018-05-14 Proceso para preparar una formulación en polvo seco que comprende un anticolinérgico, un corticosteroide y un beta-adrenérgico

Country Status (32)

Country Link
US (3) US10086003B2 (es)
EP (2) EP3689379B1 (es)
JP (1) JP6942126B2 (es)
KR (1) KR20180082442A (es)
CN (1) CN108348614B (es)
AR (1) AR106687A1 (es)
AU (1) AU2016357988B2 (es)
CA (1) CA3005291C (es)
CL (1) CL2018001297A1 (es)
CO (1) CO2018005139A2 (es)
DK (2) DK3689379T3 (es)
EA (1) EA037346B1 (es)
ES (2) ES2789365T3 (es)
GE (1) GEP20207178B (es)
HK (1) HK1256859A1 (es)
HR (2) HRP20211599T1 (es)
HU (2) HUE050343T2 (es)
IL (1) IL259327B (es)
MA (1) MA52437A (es)
MX (1) MX2018005979A (es)
MY (1) MY198321A (es)
PE (1) PE20181377A1 (es)
PH (1) PH12018501023B1 (es)
PL (2) PL3377109T3 (es)
PT (2) PT3377109T (es)
SA (1) SA518391574B1 (es)
SG (2) SG10201912090UA (es)
SI (2) SI3689379T1 (es)
TW (1) TWI729025B (es)
UA (1) UA125173C2 (es)
WO (1) WO2017085007A1 (es)
ZA (1) ZA201803167B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3060020A1 (en) 2017-05-11 2018-11-15 Chiesi Farmaceutici S.P.A. A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
CN110612095A (zh) 2017-05-11 2019-12-24 奇斯药制品公司 制备包含抗胆碱能药、皮质类固醇和β-肾上腺素能药的干粉制剂的方法
WO2019060595A1 (en) * 2017-09-20 2019-03-28 Teva Branded Pharmaceutical Products R&D, Inc. INHALABLE DRY POWDER MEDICINAL PRODUCT COMPRISING GLYCOPYRRONIUM
WO2021041374A1 (en) * 2019-08-28 2021-03-04 Cai Gu Huang Liposome formulation of fluticasone furoate and method of preparation
CN116194087A (zh) * 2020-01-15 2023-05-30 四川海思科制药有限公司 一种含茚达特罗的吸入气雾剂药物组合物及其制备方法
CN111467498A (zh) * 2020-05-14 2020-07-31 王兆霖 药物组合物制剂
CN117064869A (zh) * 2023-09-27 2023-11-17 山东京卫制药有限公司 一种胶囊型吸入粉雾剂及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20011227A1 (es) * 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0015043D0 (en) 2000-06-21 2000-08-09 Glaxo Group Ltd Medicament dispenser
ATE503517T2 (de) 2002-07-31 2011-04-15 Chiesi Farma Spa Pulverinhalator
EP1646370A1 (en) * 2003-07-11 2006-04-19 Glaxo Group Limited Pharmaceutical formulations
GB0410399D0 (en) * 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
SI2560611T1 (en) 2010-04-21 2018-03-30 Chiesi Farmaceutici S.P.A. A process for preparing particles with reduced electrostatic charges
US9393202B2 (en) 2013-04-26 2016-07-19 Chiesi Farmaceutici S.P.A Particle size reduction of an antimuscarinic compound
HUE053957T2 (hu) * 2013-07-11 2021-08-30 Chiesi Farm Spa Antikolinerg, kortikoszteroid és béta-adrenerg anyagot tartalmazó száraz porkészítmény inhalálással történõ beadásra

Also Published As

Publication number Publication date
AU2016357988B2 (en) 2021-12-16
GEP20207178B (en) 2020-11-10
JP2018537453A (ja) 2018-12-20
SI3377109T1 (sl) 2020-07-31
PH12018501023A1 (en) 2018-12-17
US10086003B2 (en) 2018-10-02
PT3689379T (pt) 2021-09-24
EP3689379B1 (en) 2021-08-11
PE20181377A1 (es) 2018-09-05
HK1256859A1 (zh) 2019-10-04
ES2789365T3 (es) 2020-10-26
AU2016357988A1 (en) 2018-05-31
TWI729025B (zh) 2021-06-01
EP3377109A1 (en) 2018-09-26
JP6942126B2 (ja) 2021-09-29
BR112018009811A2 (pt) 2018-11-13
US20190021994A1 (en) 2019-01-24
AR106687A1 (es) 2018-02-07
TW201722403A (zh) 2017-07-01
EA037346B1 (ru) 2021-03-16
PL3689379T3 (pl) 2021-12-13
DK3689379T3 (da) 2021-09-06
EP3377109B1 (en) 2020-03-04
KR20180082442A (ko) 2018-07-18
CN108348614B (zh) 2021-09-21
IL259327B (en) 2020-11-30
CA3005291C (en) 2024-01-16
ES2890409T3 (es) 2022-01-19
HUE050343T2 (hu) 2020-11-30
HUE056402T2 (hu) 2022-02-28
UA125173C2 (uk) 2022-01-26
CO2018005139A2 (es) 2018-08-10
DK3377109T3 (da) 2020-04-20
ZA201803167B (en) 2019-07-31
WO2017085007A1 (en) 2017-05-26
IL259327A (en) 2018-07-31
SI3689379T1 (sl) 2021-11-30
MA52437A (fr) 2021-05-05
US10786451B2 (en) 2020-09-29
BR112018009811A8 (pt) 2019-02-26
MY198321A (en) 2023-08-24
US20200360278A1 (en) 2020-11-19
EA201890967A1 (ru) 2018-12-28
PH12018501023B1 (en) 2018-12-17
MX2018005979A (es) 2018-08-29
SG11201804048WA (en) 2018-06-28
PL3377109T3 (pl) 2020-09-21
US10959944B2 (en) 2021-03-30
EP3689379A1 (en) 2020-08-05
GEAP201614782A (es) 2020-04-27
PT3377109T (pt) 2020-05-13
SG10201912090UA (en) 2020-02-27
HRP20211599T1 (hr) 2022-01-07
CA3005291A1 (en) 2017-05-26
US20170136034A1 (en) 2017-05-18
HRP20200571T1 (hr) 2020-07-10
CN108348614A (zh) 2018-07-31
SA518391574B1 (ar) 2021-06-13

Similar Documents

Publication Publication Date Title
CL2018001297A1 (es) Proceso para preparar una formulación en polvo seco que comprende un anticolinérgico, un corticosteroide y un beta-adrenérgico
EP3268434A4 (en) UV ABSORBENT POLYMER DYES AND METHOD OF USE THEREOF
EP3329400A4 (en) DISAMBING OF SEARCH QUESTIONS
ZA201902762B (en) Mission-critical push-to-talk
EP3334551B8 (en) Locking chuck
GB2575532B (en) Porous, wet-triggered shrinkable materials
EP3315626A4 (en) Bolt
CL2016001202S1 (es) Neumatico.
CL2018000420A1 (es) Nuevo derivado de catecol y composición farmacéutica que comprende el mismo.
EP3276832A4 (en) Synthesizer
ZA201807867B (en) Radial parallel sawing
PL3277447T3 (pl) Prasa promieniowa
ES1132430Y (es) Dispositivo para herrar perfeccionado.
EP3504805A4 (en) EFFICIENT SEARCH BY ANTENNA SAMPLE GROUP
EP3384261A4 (en) INSTRUMENTED SPINDLE OR LOAD CELL FOR HIGH LOAD, HIGH RESOLUTION
EP3305959A4 (en) DRY
EP3285947A4 (en) Chuck arrangement
GB2553882B (en) Multi-pressure type condenser
AU2017161V (en) GR13008 Grevillea .
AU2017160V (en) GR13002 Grevillea .
GB201715900D0 (en) Palate-transducers & palate-loudspeakers, new drawings
GB201719895D0 (en) Dna, methods etc
GB201719896D0 (en) Dna, methods etc
GB201716049D0 (en) The E.M.S as energy
GB201511984D0 (en) The next step in search. gazambo